Салусин-α и -β в качестве новых биологических маркёров при сердечно-сосудистых заболеваниях: обзор литературы
- Авторы: Алиева А.М.1, Резник Е.В.1, Теплова Н.В.1, Гызыева М.Х.2, Рахаев А.М.3, Котикова И.А.1, Никитин И.Г.1
-
Учреждения:
- Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
- Пятигорский медико-фармацевтический институт
- Главное бюро медико-социальной экспертизы
- Выпуск: Том 14, № 4 (2023)
- Страницы: 257-268
- Раздел: Обзоры
- URL: https://journals.rcsi.science/2221-7185/article/view/232030
- DOI: https://doi.org/10.17816/CS568593
- ID: 232030
Цитировать
Полный текст
Аннотация
Несмотря на значительные достижения медицины, сердечно-сосудистые заболевания продолжают оставаться ведущей причиной смертности во всём мире. Важной задачей кардиологии являются поиск и изучение новых сердечно- сосудистых биологических маркёров. В последние годы интерес учёных привлекают салусины. Салусины являются эндогенными биологически активными пептидами, которые впервые были идентифицированы в 2003 году. Проведённые к настоящему времени исследования продемонстрировали, что салусин-α и -β играют важную роль в ремоделировании сосудов, при воспалении, артериальной гипертензии и атеросклеротических процессах. Салусин-α проявляет антиатерогенное действие, тогда как салусин-β играет проатерогенную роль. Несмотря на разнообразные биологические, физиологические и патофизиологические аспекты салуcинов, точный механизм их сердечно-сосудистых эффектов до конца не известен. Необходимы дальнейшие глубинные исследования роли салусинов при сердечно- сосудистых заболеваниях. Регуляция концентрации и экспрессии салусина-α и -β, возможно, окажется многообещающей стратегией для лечения больных кардиологического профиля.
Полный текст
Открыть статью на сайте журналаОб авторах
Амина Магомедовна Алиева
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Автор, ответственный за переписку.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579
SPIN-код: 2749-6427
канд. мед. наук, доцент
Россия, МоскваЕлена Владимировна Резник
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Email: elenaresnik@gmail.com
ORCID iD: 0000-0001-7479-418X
SPIN-код: 3494-9080
д-р мед. наук, профессор
Россия, МоскваНаталья Вадимовна Теплова
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Email: teplova.nv@yandex.ru
ORCID iD: 0000-0002-7181-4680
SPIN-код: 9056-1948
д-р мед. наук, профессор
Россия, МоскваМалика Хасымовна Гызыева
Пятигорский медико-фармацевтический институт
Email: amisha_alieva@mail.ru
ORCID iD: 0009-0008-9105-1191
студент
Россия, ПятигорскАлик Магомедович Рахаев
Главное бюро медико-социальной экспертизы
Email: alikrahaev@yandex.ru
ORCID iD: 0000-0001-9601-1174
SPIN-код: 5166-8100
д-р мед. наук, профессор
Россия, НальчикИрина Александровна Котикова
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Email: kotikova.ia@mail.ru
ORCID iD: 0000-0001-5352-8499
SPIN-код: 1423-7300
студент
Россия, МоскваИгорь Геннадиевич Никитин
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова
Email: igor.nikitin.64@mail.ru
ORCID iD: 0000-0003-1699-0881
SPIN-код: 3595-1990
д-р мед. наук, профессор
Россия, МоскваСписок литературы
- Zdravookhranenie v Rossii. 2019: Stat. sb. Moscow: Rosstat; 2019. (In Russ).
- O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2019 godu: Gosudarstvennyi doklad. Moscow: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka; 2020. (In Russ).
- Alieva AM. Natriiureticheskie peptidy: ispol'zovanie v sovremennoi kardiologii. Atmosfera. Novosti kardiologii. 2017;1:26–31. (In Russ).
- Alieva AM, Pinchuk TV, Voronkova KV, et al. Neopterin is a biomarker of chronic heart failure (review of modern literature). Consilium Medicum. 2021;23(10):756–759. (In Russ). doi: 10.26442/20751753.2021.10.201113
- Aliyevа AM, Almazova II, Pinchuk TV, et al. The value of copeptin in the diagnosis and prognosis of cardiovascular diseases. Clinical Medicine (Russian Journal). 2020;98(3):203–209. (In Russ). doi: 10.30629/0023-2149-2020-98-3-203-209
- Alieva AM, Teplova NV, Kislyakov VA, et al. Biomarkers in cardiology: microRNA and heart failure. Therapy. 2022;1:60–70. (In Russ). doi: 10.18565/therapy.2022.1.60-70
- Shichiri M, Ishimaru S, Ota T, et al. Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med. 2003;9(9):1166–1172. doi: 10.1038/nm913
- Janecka A, Stefanowicz J. Use of salusin β for predicting atherosclerosis and components of the metabolic syndrome. Adv Clin Exp Med. 2023. doi: 10.17219/acem/166535. Epub ahead of print.
- Chen MX, Deng BY, Liu ST, et al. Salusins: advance in cardiovascular disease research. J Pharm Pharmacol. 2023;75(3):363–369. doi: 10.1093/jpp/rgac087
- Sato K, Watanabe R, Itoh F, et al. Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases. Int J Hypertens. 2013;2013:965140. doi: 10.1155/2013/965140
- Watanabe T, Sato K, Itoh F, et al. The roles of salusins in atherosclerosis and related cardiovascular diseases. J Am Soc Hypertens. 2011;5(5):359–365. doi: 10.1016/j.jash.2011.06.003
- Koya T, Miyazaki T, Watanabe T, et al. Salusin-β accelerates inflammatory responses in vascular endothelial cells via NF-κB signaling in LDL receptor-deficient mice in vivo and HUVECs in vitro. Am J Physiol Heart Circ Physiol. 2012;303(1):H96–H105. doi: 10.1152/ajpheart.00009.2012
- Esfahani M, Saidijam M, Goodarzi MT, et al. Salusin-α Attenuates Inflammatory Responses in Vascular Endothelial Cells. Biochemistry (Mosc). 2017;82(11):1314–1323. doi: 10.1134/S0006297917110098
- Zhou CH, Liu L, Liu L, et al. Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway. PLoS One. 2014;9(3):e91468. doi: 10.1371/journal.pone.0091468
- Chen H, Jin G. Downregulation of Salusin-β protects renal tubular epithelial cells against high glucose-induced inflammation, oxidative stress, apoptosis and lipid accumulation via suppressing miR-155-5p. Bioengineered. 2021;12(1):6155–6165. doi: 10.1080/21655979.2021
- Wang H, Zhang M, Zhou H, et al. Salusin-β Mediates High Glucose-Induced Inflammation and Apoptosis in Retinal Capillary Endothelial Cells via a ROS-Dependent Pathway in Diabetic Retinopathy. Diabetes Metab Syndr Obes. 2021;14:2291–2308. doi: 10.2147/DMSO.S301157
- Xu T, Zhang Z, Liu T, et al. Salusin-β contributes to vascular inflammation associated with pulmonary arterial hypertension in rats. J Thorac Cardiovasc Surg. 2016;152(4):1177–1187. doi: 10.1016/j.jtcvs.2016.05.056
- Zhou CH, Pan J, Huang H, et al. Salusin-β, but not salusin-α, promotes human umbilical vein endothelial cell inflammation via the p38 MAPK/JNK-NF-κB pathway. PLoS One. 2014;9(9):e107555. doi: 10.1371/journal.pone.0107555
- Li HB, Yu XJ, Bai J, et al. Silencing salusin β ameliorates heart failure in aged spontaneously hypertensive rats by ROS-relative MAPK/NF-κB pathways in the paraventricular nucleus. Int J Cardiol. 2019;280:142–151. doi: 10.1016/j.ijcard.2018
- Qian K, Feng L, Sun Y, et al. Overexpression of Salusin-α Inhibits Vascular Intimal Hyperplasia in an Atherosclerotic Rabbit Model. Biomed Res Int. 2018;2018:8973986. doi: 10.1155/2018/8973986
- Sun HJ, Zhao MX, Liu TY, et al. Salusin-β induces foam cell formation and monocyte adhesion in human vascular smooth muscle cells via miR155/NOX2/NFκB pathway. Sci Rep. 2016;6:23596. doi: 10.1038/srep23596
- Sun HJ, Liu TY, Zhang F, et al. Salusin-β contributes to vascular remodeling associated with hypertension via promoting vascular smooth muscle cell proliferation and vascular fibrosis. Biochim Biophys Acta. 2015;1852(9):1709–1718. doi: 10.1016/j.bbadis.2015.05.008
- Wang X, Chen A, Hu R, et al. Salusin-β, a TOR2A gene product, promotes proliferation, migration, fibrosis, and calcification of smooth muscle cells and accelerates the imbalance of vasomotor function and vascular remodeling in monocrotaline-induced pulmonary hypertensive rats. Front Pharmacol. 2022;13:928834. doi: 10.3389/fphar.2022.928834
- Gao S, Xu L, Zhang Y, et al. Salusin-α Inhibits Proliferation and Migration of Vascular Smooth Muscle Cell via Akt/mTOR Signaling. Cell Physiol Biochem. 2018;50(5):1740–1753. doi: 10.1159/000494792
- Pan Y, Sun S, Wang X, et al. Improvement of Vascular Function by Knockdown of Salusin-β in Hypertensive Rats via Nitric Oxide and Reactive Oxygen Species Signaling Pathway. Front Physiol. 2021;12:622954. doi: 10.3389/fphys.2021.622954
- Li HB, Qin DN, Cheng K, et al. Central blockade of salusin β attenuates hypertension and hypothalamic inflammation in spontaneously hypertensive rats. Sci Rep. 2015;5:11162. doi: 10.1038/srep11162
- Sun S, Zhang F, Pan Y, et al. A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats. Cardiovasc Drugs Ther. 2021;35(1):125–139. doi: 10.1007/s10557-020-06983-1
- Ren XS, Ling L, Zhou B, et al. Silencing salusin-β attenuates cardiovascular remodeling and hypertension in spontaneously hypertensive rats. Sci Rep. 2017;7:43259. doi: 10.1038/srep43259
- Xu XL, Zeng Y, Zhao C, et al. Salusin-β induces smooth muscle cell proliferation by regulating cyclins D1 and E expression through MAPKs signaling pathways. J Cardiovasc Pharmacol. 2015;65(4):377–385. doi: 10.1097/FJC.0000000000000209
- Pan Y, Chen A, Wang X, et al. Saluisn-β contributes to endothelial dysfunction in monocrotaline-induced pulmonary arterial hypertensive rats. Biomed Pharmacother. 2022;155:113748. doi: 10.1016/j.biopha.2022.113748
- Xu Y, Fei X, Fu H, et al. Upregulated expression of a TOR2A gene product-salusin-β in the paraventricular nucleus enhances sympathetic activity and cardiac sympathetic afferent reflex in rats with chronic heart failure induced by coronary artery ligation. Acta Physiol (Oxf). 2023;238(4):e13987. doi: 10.1111/apha.13987
- Huang X, Wang Y, Ren K. Deleterious effect of salusin-β in paraventricular nucleus on sympathetic activity and blood pressure via NF-κB signaling in a rat model of obesity hypertension. Pharmazie. 2015;70(8):543–548.
- Xu Y, Pan Y, Wang X, et al. Knockdown of Salusin-β Improves Cardiovascular Function in Myocardial Infarction-Induced Chronic Heart Failure Rats. Oxid Med Cell Longev. 2021;2021:8896226. doi: 10.1155/2021/8896226
- Zhou CH, Liu LL, Wu YQ, et al. Enhanced expression of salusin-β contributes to progression of atherosclerosis in LDL receptor deficient mice. Can J Physiol Pharmacol. 2012;90(4):463–471. doi: 10.1139/y2012-022
- Nagashima M, Watanabe T, Shiraishi Y, et al. Chronic infusion of salusin-alpha and -beta exerts opposite effects on atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis. 2010;212(1):70–77. doi: 10.1016/j.atherosclerosis.2010.04.027
- Sun H, Zhang F, Xu Y, et al. Salusin-β Promotes Vascular Calcification via Nicotinamide Adenine Dinucleotide Phosphate/Reactive Oxygen Species-Mediated Klotho Downregulation. Antioxid Redox Signal. 2019;31(18):1352–1370. doi: 10.1089/ars.2019.7723
- Zhang H, Yang C, Wang S, et al. Overexpression of salusin α upregulates AdipoR2 and activates the PPARα/ApoA5/SREBP 1c pathway to inhibit lipid synthesis in HepG2 cells. Int J Mol Med. 2023;51(5):41. doi: 10.3892/ijmm.2023.5244
- Zhao MX, Zhou B, Ling L, et al. Salusin-β contributes to oxidative stress and inflammation in diabetic cardiomyopathy. Cell Death Dis. 2017;8(3):e2690. doi: 10.1038/cddis.2017.106
- Esfahani M, Saidijam M, Najafi R, et al. The effect of salusin-β on expression of pro- and anti-inflammatory cytokines in human umbilical vein endothelial cells (HUVECs). ARYA Atheroscler. 2018;14(1):1–10. doi: 10.22122/arya.v14i1.1602
- Watanabe T, Suguro T, Sato K, et al. Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res. 2008;31(3):463–468. doi: 10.1291/hypres.31.463
- Wang Y, Wang S, Zhang J, et al. Salusin-β is superior to salusin-α as a marker for evaluating coronary atherosclerosis. J Int Med Res. 2020;48(2):300060520903868. doi: 10.1177/0300060520903868
- Argun D, Argun F, Borku Uysal B. Evaluation of salusin-α and salusin-β levels in patients with type 2 diabetes mellitus and determination of the impact of severity of hyperglycemia on salusin levels. Ir J Med Sci. 2021;190(4):1403–1411. doi: 10.1007/s11845-021-02674-4
- Yılmaz E, Kurt D, Aydın E, et al. A New Marker for Determining Cardiovascular Risk: Salusin Alpha. Cureus. 2022;14(10):e30340. doi: 10.7759/cureus.30340
- Liu J, Ren YG, Zhang LH, et al. Serum salusin-β levels are associated with the presence and severity of coronary artery disease. J Investig Med. 2015;63(4):632–635. doi: 10.1097/JIM.0000000000000184
- Arkan A, Atukeren P, Ikitimur B, et al. The importance of circulating levels of salusin-α, salusin-β, and heregulin-β1 in atherosclerotic coronary arterial disease. Clin Biochem. 2021;87:19–25. doi: 10.1016/j.clinbiochem.2020.10.003
- Yildirim A, Kucukosmanoglu M. Relationship between Serum Salusin Beta Levels and Coronary Artery Ectasia. Acta Cardiol Sin. 2021;37(2):130–137. doi: 10.6515/ACS.202103_37(2).20200910A
- Akyüz A, Aydın F, Alpsoy Ş, et al. Relationship of serum salusin beta levels with coronary slow flow. Anatol J Cardiol. 2019;22(4):177–184. doi: 10.14744/AnatolJCardiol.2019.43247
- Alpsoy S, Dogan B, Ozkaramanli Gur D, et al. Assessment of salusin alpha and salusin beta levels in patients with newly diagnosed dipper and non-dipper hypertension. Clin Exp Hypertens. 2021;43(1):42–48. doi: 10.1080/10641963.2020.1797086
- Fujie S, Hasegawa N, Sanada K, et al. Increased serum salusin-α by aerobic exercise training correlates with improvements in arterial stiffness in middle-aged and older adults. Aging (Albany NY). 2020;12(2):1201–1212. doi: 10.18632/aging.102678
- Zhang W, Zhang J, Jin F, Zhou H. Efficacy of felodipine and enalapril in the treatment of essential hypertension with coronary artery disease and the effect on levels of Salusin-β, Apelin, and PON1 gene expression in patients. Cell Mol Biol (Noisy-le-grand). 2022;67(6):174–180. doi: 10.14715/cmb/2021.67.6.24
- Genç Elden S, Yılmaz MS, Altındiş M, et al. The role of serum salusin alpha and beta levels and atherosclerotic risk factors in idiopathic sudden hearing loss pathogenesis. Eur Arch Otorhinolaryngol. 2022;279(3):1311–1316. doi: 10.1007/s00405-021-06804-7
- Yassien M, Fawzy O, Mahmoud E, Khidr EG. Serum salusin-β in relation to atherosclerosis and ventricular dysfunction in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2020;14(6):2057–2062. doi: 10.1016/j.dsx.2020.10.025
- Nazari M, Minasian V, Hovsepian S. Effects of Two Types of Moderate- and High-Intensity Interval Training on Serum Salusin-α and Salusin-β Levels and Lipid Profile in Women with Overweight/Obesity. Diabetes Metab Syndr Obes. 2020;13:1385–1390. doi: 10.2147/DMSO.S248476
- Sipahi S, Genc AB, Acikgoz SB, et al. Relationship of salusin-alpha and salusin-beta levels with atherosclerosis in patients undergoing haemodialysis. Singapore Med J. 2019;60(4):210–215. doi: 10.11622/smedj.2018123
- Močnik M, Marčun Varda N. Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin. Children (Basel). 2022;9(1):102. doi: 10.3390/children9010102
- Kolakowska U, Kuroczycka-Saniutycz E, Wasilewska A, Olański W. Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population? Pediatr Nephrol. 2015;30(3):523–531. doi: 10.1007/s00467-014-2960-y
- Kolakowska U, Kuroczycka-Saniutycz E, Olanski W, Wasilewska A. Correlation of Salusin Beta with hs-CRP and ADMA in Hypertensive Children and Adolescents. Curr Pharm Des. 2018;24(30):3551–3557. doi: 10.2174/1381612824666180607124531
- Dervişoğlu P, Elmas B, Kösecik M, et al. Salusin-α levels are negatively correlated with diastolic blood pressure in children with obesity. Cardiol Young. 2019;29(10):1225–1229. doi: 10.1017/S1047951119001173
- Paahoo A, Tadibi V, Behpoor N. Effectiveness of Continuous Aerobic Versus High-Intensity Interval Training on Atherosclerotic and Inflammatory Markers in Boys With Overweight/Obesity. Pediatr Exerc Sci. 2021;33(3):132–138. doi: 10.1123/pes.2020-0138